Display options
Cite
Vannini M, Emery S, Lieutier-Colas F, et al. Epidemiology of candidemia in NICE area, France: A five-year study of antifungal susceptibility and mortality. J Mycol Med. 2021;32(1):101210doi: 10.1016/j.mycmed.2021.101210.
Vannini, M., Emery, S., Lieutier-Colas, F., Legueult, K., Mondain, V., Retur, N., Gastaud, L., Pomares, C., & Hasseine, L. (2021). Epidemiology of candidemia in NICE area, France: A five-year study of antifungal susceptibility and mortality. Journal de mycologie medicale, 32(1), 101210. https://doi.org/10.1016/j.mycmed.2021.101210
Vannini, M, et al. "Epidemiology of candidemia in NICE area, France: A five-year study of antifungal susceptibility and mortality." Journal de mycologie medicale vol. 32,1 (2021): 101210. doi: https://doi.org/10.1016/j.mycmed.2021.101210
Vannini M, Emery S, Lieutier-Colas F, Legueult K, Mondain V, Retur N, Gastaud L, Pomares C, Hasseine L. Epidemiology of candidemia in NICE area, France: A five-year study of antifungal susceptibility and mortality. J Mycol Med. 2021 Oct 21;32(1):101210. doi: 10.1016/j.mycmed.2021.101210. Epub 2021 Oct 21. PMID: 34768155.
Copy Download .nbib Format: NLM
Share it on

J Mycol Med. 2021 Oct 21;32(1):101210. doi: 10.1016/j.mycmed.2021.101210. Epub 2021 Oct 21.

Epidemiology of candidemia in NICE area, France: A five-year study of antifungal susceptibility and mortality.

Journal de mycologie medicale

M Vannini, S Emery, F Lieutier-Colas, K Legueult, V Mondain, N Retur, L Gastaud, C Pomares, L Hasseine

Affiliations

  1. Service de Parasitologie Mycologie, Centre Hospitalier Universitaire de NICE 06200, France.
  2. Service de la Pharmacie Centre Hospitalier Universitaire de NICE 06200, France.
  3. Service d'Infectiologie, Centre Hospitalier Universitaire de NICE 06200, France.
  4. Unité de soins continus en hématologie, Centre Antoine Lacassagne, NICE 06000, France.
  5. Service de Parasitologie Mycologie, Centre Hospitalier Universitaire de NICE 06200, France; INSERM 1065 Equipe 6 C3M, Université Côte d'Azur, France.
  6. Service de Parasitologie Mycologie, Centre Hospitalier Universitaire de NICE 06200, France. Electronic address: [email protected].

PMID: 34768155 DOI: 10.1016/j.mycmed.2021.101210

Abstract

OBJECTIVES: The aim of this study was to investigate the epidemiology of candidemia, the fungal susceptibility, the first-line therapy and the morality rate over 5 years. Knowing the differences of the yeasts in the candidemia local epidemiology, is essential to obtain information on fungal epidemiology to adapt antifungal strategies.

MATERIALS/METHODS: This retrospective study was conducted from January 2014 to December 2018. The susceptibility of the Candida strains were tested for amphotericin B, caspofungin, voriconazole and fluconazole.

RESULTS: The 304 strains were isolated from 290 patients (40 patients in 2014, 65 in 2015, 72 in 2016, 62 in 2017 and 51 in 2018). The three most common Candida spp isolated from blood cultures were Candida albicans (44%), Candida glabrata (22%) and Candida parapsilosis (13%). The proportion of non-albicans Candida decreased from 68% in 2014 to 45% in 2018. C. albicans and C. parapsilosis were to the four antifungals tested. As first-line therapy, 60% of patients received caspofungin and 26% fluconazole. There was no significant difference in the mortality between the two arms of patients (, 27% and 21%, p = 0.47 at 30 days respectively). Thirty day all-cause mortality was 31% and it decreased from 2014 (46%) to 2018 (18%).

CONCLUSIONS: We report that the absence of antifungal resistance of our C. albicans and C. parapsilosis candidemia suggests possible treatment after MALDI-TOF identification with fluconazole as first-line therapy in our hospital, as soon as possible and while continuing to perform the antifungal test.

Copyright © 2021 SFMM. Published by Elsevier Masson SAS. All rights reserved.

Keywords: Antifungal susceptibility testing; Candidemia; Epidemiology; Fluconazole; Invasive fungal infection; Mortality; Non-albicans Candida

Conflict of interest statement

Declaration of Competing Interest Authors declare no conflict of interest

Publication Types